Bizengri savings card: as little as $10 a dose with commercial insurance

Bizengri is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Bizengri is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameBizengri

Authorized genericzenocutuzumab

Regular genericzenocutuzumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Bizengri?

The original

–

Brand nameThe maker’s card

PTx Assist Co-Pay Assistance Program

Savings card from Merus

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $10 a dose

The card takes up to $25,000 a year off your co-pay.

Or call 1-877-353-8546. See the offer on ptxassist.com

In the maker’s words

“If you have commercial insurance, and qualify for this program, you may be able to reduce your out-of-pocket costs to as little as $0 for the first dose and $10 for subsequent doses…”

From the maker’s offer on ptxassist.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Bizengri itself, from the same company, sold without the brand name, and usually for less. For now Bizengri is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Bizengri is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of:

Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.*
Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.*
Adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Bizengri (Partner Therapeutics, Inc.), May 19, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/bizengri/